Pfizer makes $100 million bid for ResApp Health

Pharmaceutical giant Pfizer has made an offer worth approximately $100 million to buy 100 per cent of the shares in AXS-listed respiratory health software developer ResApp Health.

ResApp and Pfizer have also entered into a research and development license agreement to work together on R&D for products in the field of COVID-19. ResApp recently announced it was planning a randomised control trial of its new app-based diagnostic screening tool for COVID-19.

Posted in Australian eHealth

Tags: ResApp Health, Pfizer

You need to log in to post comments. If you don't have a Pulse+IT website account, click here to subscribe.

Sign up for Pulse+IT eNewsletters

Sign up for Pulse+IT website access

For more information, click here.

Copyright © 2022 Pulse+IT Communications Pty Ltd
No content published on this website can be reproduced by any person for any reason without the prior written permission of the publisher.
Supported by Social Media Agency | pepperit